Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-22
2010-12-14
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S360100
Reexamination Certificate
active
07851498
ABSTRACT:
This invention is directed to a hexahydro-cyclooctyl pyrazole cannabinoid modulator compound of formula (I):and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.
REFERENCES:
patent: 2948718 (1960-08-01), Schindler
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 4486354 (1984-12-01), Baxter et al.
patent: 4513006 (1985-04-01), Maryanoff
patent: 4699927 (1987-10-01), Deboeck
patent: 5242942 (1993-09-01), Costanzo et al.
patent: 5384327 (1995-01-01), Costanzo et al.
patent: 2005/0228034 (2005-10-01), Lagu et al.
patent: 2006/0089378 (2006-04-01), Xia et al.
patent: WO 01/32629 (2001-05-01), None
patent: WO 01/32663 (2001-05-01), None
patent: WO 2005/095353 (2005-10-01), None
patent: WO 2006/030124 (2006-03-01), None
patent: WO 2006/030124 (2006-06-01), None
IUPAC Recommendations for Fundamental Stereochemistry (Section E),Pure Appl. Chem., 1976, 45:13-30.
Rinaldi-Carmona, M., Calandra, B., Shire, D., Bouaboula, M., Oustric, D., Barth, F., Casellas, P., Ferrara, P. and Le Fur, G. (1996)J. Pharmacol. Exp. Ther., 278:871-878.
Munro, S., Thomas, K.L. and Abu-Shaar, M. (1993)Nature, 365: 61-65.
Kimball E.S., Palmer J.M., D'Andrea M.R., Hornby P.J. and Wade P.R., Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice,Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 288: G1266-1273.
Blumberg R.S., Saubermann L.J. and Strober W., Animal models of mucosal inflammation and their relation to human inflammatory bowel disease,Current Opinion in Immunology, 1999, vol. 11: 648-656.
Egger B., Bajaj-Elliott M., MacDonald T.T., Inglin R., Eysselein, V.E. and Buchler M.W., Characterization of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency,Digestion, 2000, vol. 62: 240-248.
Stevceva L., Pavli P., Husband A.J. and Doe, W.F., The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it,BMC Clinical Pathology, 2001, vol. 1: 3-13.
Diaz-Granados, Howe K., Lu J. and McKay D.M., Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity,Amer. J. Pathology, 2000, vol. 156: 2169-2177.
Holte, K. and H. Kehlet (2000). “Postoperative ileus: a preventable event.”Br J Surg87(11): 1480-93.
Livingston, E. H. and E. P. Passaro (1990) “Postoperative ileus.”Digestive Diseases and Sciences35(1): 121-132.
Bauer, A. J., N. T. Schwarz, et al. (2002) “Ileus in critical illness: mechanisms and management.”Curr Opin Crit Care8(2): 152-7.
Mikkelsen, H. B. (1995) “Macrophages in the external muscle layers of mammalian intestines.”Histology and Histopathology10: 719-736.
Kalff, J. C., W. H. Schraut, et al. (1998) “Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in paralytic ileus.”Annals of Surgery228: 652-663.
Kalff, Schraut, et al. (1998); Kalff, J. C., N. T. Schwarz, et al. (1998) “Leukocytes of the intestinal muscularis: their phenotype and isolation.”J Leukoc Biol63(6): 683-91.
Josephs, M. D., G. Cheng, et al. (1999) “Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility.”J Surg Res86(1): 50-4.
Kalff, J. C., T. M. Carlos, et al. (1999) “Surgically induced leukocytic infiltrates within the rat intestinal muscularis mediate postoperative ileus.”Gastroenterology117: 378-387.
Kalff, J. C., W. H. Schraut, et al. (2000) “Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents.”Gastroenterology118(2): 316-27.
Kalff, J. C., N. T. Schwarz, et al. (1997) “Phagocyte activation and infiltration of the intestinal muscularis with impairment of small bowel motility after surgical manipulation.”Langenbecks Archiv für ChirurgieSuppl.: 425-428.
Wehner, S., N. T. Schwarz, et al. (2005) “Induction of IL-6 within the rodent intestinal muscularis after intestinal surgical stress.”Surgery137(4): 436-46.
Kalff, J. C., B. M. Buchholz, et al. (1999) “Biphasic response to gut manipulation and temporal correlation of cellular infiltrates and muscle dysfunction in rat.”Surgery126(3): 498-509.
von Ritter, C., R. Be, et al. (1989) “Neutrophilic proteases: mediators of formyl-methionyl-leucyl-phenylalanine-induced ileitis in rats.”Gastroenterology97(3): 605-9.
Bielefeldt, K. and J. L. Conklin (1997) “Intestinal motility during hypoxia and reoxygenation in vitro.”Dig Dis Sci42(5): 878-84.
Mahmoudian, “The Cannabinoid Receptor: Computer-Aided Molecular Modeling and Docking of Ligands”, Journal of Molecular Graphics and Modeling, Jun. 1997, vol. 15, pp. 149-153.
PCT International Search Report, dated Feb. 6, 2007, for PCT Int'l. Appln. No. PCT/US2006/037350.
Liotta Fina
Lu Huajun
Pan Meng
Wachter Michael P.
Xia Mingde
Dodd Thomas J.
Janssen Pharmaceutica NV
Saeed Kamal A
LandOfFree
Hexahydro-cyclooctyl pyrazole cannabinoid modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hexahydro-cyclooctyl pyrazole cannabinoid modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hexahydro-cyclooctyl pyrazole cannabinoid modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190866